Jaguar Health, Inc. (NASDAQ:JAGX)

BRIEF

published on 09/24/2025 at 15:05, 4 months 5 days ago

Jaguar Health Seeks Orphan Drug Designation for Crofelemer

FDA Crofelemer Orphan Drug Designation Breast Cancer Brain Metastasis
PRESS RELEASE

published on 09/24/2025 at 15:00, 4 months 5 days ago

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition
Jaguar Health's Napo Pharmaceuticals submits orphan drug designation application to FDA for crofelemer in treating diarrhea in adult patients with breast cancer metastasized to the brain, targeting expedited regulatory pathways

FDA Napo Pharmaceuticals Crofelemer Jaguar Health Breast Cancer
BRIEF

published on 09/23/2025 at 15:05, 4 months 6 days ago

Jaguar Health to Present at Key Conferences in September 2025

Jaguar Health Plant-based Medicines FDA-approved Drug Virtual Conferences Gastrointestinal Treatments
PRESS RELEASE

published on 09/23/2025 at 15:00, 4 months 6 days ago

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. announces CEO Lisa Conte's virtual presentations at upcoming conferences. The company focuses on developing plant-derived medicines for gastrointestinal distress

Pharmaceuticals Gastrointestinal Distress Jaguar Health Lisa Conte Virtual Presentations
BRIEF

published on 09/05/2025 at 15:05, 4 months 24 days ago

Jaguar Health to Present at H.C. Wainwright Global Investment Conference

Pharmaceuticals Jaguar Health Conference Presentation H.C. Wainwright Gastrointestinal Health
PRESS RELEASE

published on 09/05/2025 at 15:00, 4 months 24 days ago

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present at H.C. Wainwright 27th Annual Global Investment Conference. Lisa Conte to discuss pharmaceutical developments for gastrointestinal distress

Pharmaceuticals Gastrointestinal Distress Lisa Conte Jaguar Health Inc. H.C. Wainwright Conference
BRIEF

published on 08/21/2025 at 15:05, 5 months 8 days ago

Jaguar Health Targets Global Expansion for Canalevia®

FDA Approval Jaguar Health Canalevia Dog Diarrhea Treatment Animal Health Summit
PRESS RELEASE

published on 08/21/2025 at 15:00, 5 months 8 days ago

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Jaguar Health announces conditional FDA approval of Canalevia-CA1 for CID in dogs and strategic plans to expand indication for general diarrhea treatment globally. Participation in 2025 Animal Health Summit

FDA Approval Canalevia-CA1 Partnerships Animal Health Diarrhea Treatment
BRIEF

published on 08/19/2025 at 22:20, 5 months 10 days ago

Jaguar Health Announces Approval of All Proposals at Annual Meeting

Crofelemer FDA Approval Jaguar Health Annual Meeting Partnership Strategy
PRESS RELEASE

published on 08/19/2025 at 22:15, 5 months 10 days ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Jaguar CEO Lisa Conte to provide updates on crofelemer trial results and regulatory pathway at Emerging Growth Conference. Annual meeting results and company strategy also discussed

Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference Regulatory Pathway

Published on 01/30/2026 at 08:35, 2 hours 47 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 3 hours 22 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 9 hours 7 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 11 hours 22 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 12 hours 22 minutes ago

PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A

View all ACCESSWIRE

Published on 01/30/2026 at 10:30, 52 minutes ago

ASTA ENERGY SOLUTIONS AG SUCCESSFULLY COMPLETES IPO
Published on 01/30/2026 at 10:00, 1 hour 22 minutes ago

Appointment of Managing Director of Tradegate BSX
Published on 01/30/2026 at 09:00, 2 hours 21 minutes ago

Original-Research: 123fahrschule SE (von NuWays AG): BUY
Published on 01/30/2026 at 09:00, 2 hours 21 minutes ago

Original-Research: q.beyond AG (von NuWays AG): BUY
Published on 01/30/2026 at 09:00, 2 hours 22 minutes ago

Official List Notice

View all EQS

Published on 01/30/2026 at 08:00, 3 hours 22 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 17 hours 22 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 17 hours 37 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 17 hours 37 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 17 hours 42 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News